Method for inducing oligodendrocyte precursor cells from OCT4-induced human somatic cells through direct reprogramming
AssigneeStemlab Inc.
InventorsSeung Kwon You, Won-Jin Yun, Min Ji Park, Ji-Yong Park
Life of this patent
Estimating the term…
Abstract
Provided is a method of inducing oligodendrocyte precursor cells (OPCs) through direct reprogramming from human somatic cells into which a nucleic acid molecule encoding an Oct4 protein or Oct4 protein-treated human somatic cells. The method of inducing OPCs by treating Oct4-overexpressing human somatic cells with a low molecular weight substance may establish OPCs with high efficiency in a short period of time through direct reprogramming without via neural stem cells, and thus the OPCs are useful as a cell therapeutic agent for an intractable demyelinating disease.
Claims12
A method of inducing oligodendrocyte from human somatic cells, comprising:
- (a) inducing oligodendrocyte precursor cells (OPCs) by culturing human somatic cells, into which a nucleic acid molecule encoding an Oct4 protein is introduced, in a medium containing (i) a TGF-β type I receptor inhibitor;
- (ii) an inhibitor of Rho-associated kinase (ROCK inhibitor);
- (iii) a histone deacetylase inhibitor;
- and (iv) a sonic hedgehog agonist (Shh agonist), and
- (b) culturing the induced OPCs in a medium containing an inhibitor of Rho-associated kinase (ROCK inhibitor), a calcium channel agonist and a leukemia inhibitory factor (LIF).
A method of inducing oligodendrocyte from human somatic cells, comprising:
- (a) inducing oligodendrocyte precursor cells (OPCs) by culturing human somatic cells in a medium containing (i) a TGF-β type I receptor inhibitor;
- (ii) an inhibitor of Rho-associated kinase (ROCK inhibitor);
- (iii) a histone deacetylase inhibitor;
- and (iv) a sonic hedgehog agonist (Shh agonist), wherein the human somatic cells are treated with an Oct4 protein before, during or after the culture, and
- (b) culturing the induced OPCs in a medium containing an inhibitor of Rho-associated kinase (ROCK inhibitor), a calcium channel agonist and a leukemia inhibitory factor (LIF).
Dependencies are inferred from the claim text.